



Medivir appoints new CMO

10 September 2018 | News

Dr. Basse will report to CEO Christine Lind and join the Medivir Executive Team.



Singapore - Medivir AB announced it has appointed Linda Basse as Chief Medical Officer effective October 1, 2018. Dr. Basse will report to CEO Christine Lind and join the Medivir Executive Team.

Dr. Basse has more than 18 years of drug development and medical marketing experience, including approvals and marketing of new cancer therapies. Her previous roles include Medical Director at Zealand Pharma with responsibility for an orphan disease drug candidate and Medical Director at Genmab with responsibilities leading to the approval of daratumumab and indication expansion of ofatumumab in hematology-oncology indications. She also held the position as Medical Director at Topotarget developing drugs for cancer, along with Medical Manager and Medical Advisor roles at Abbott Laboratories, Nycomed and NovoNordisk.

"I am very excited to join Medivir with its broad portfolio of drug candidates with the potential to improve the lives of patients. I look forward to developing these drugs to market approvals for Medivir and in collaboration with its partners", said Linda Basse.